Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Targeting bromodomain and extraterminal proteins in cardiovascular disease: Pathological mechanisms and therapeutic applications.

Created on 10 Jul 2026

Authors

Kaixuan Zhang, Yangkai Fan, Yuan Wang

Published in

The Journal of international medical research. Volume 54. Issue 7. Pages 3000605261465295. Epub Jul 09, 2026.

Abstract

Bromodomain and extraterminal proteins have emerged as key epigenetic regulators that coordinate transcriptional programs fundamental to cardiovascular physiology and disease. Although bromodomain and extraterminal protein inhibitors exert multiple cardiovascular effects, they cannot fully explain clinical heterogeneity in outcomes and responses, highlighting the need to clarify the context- and disease-specific roles of individual bromodomain and extraterminal protein family members. This narrative review delineates the distinct molecular roles of bromodomain-containing protein 2, bromodomain-containing protein 3, bromodomain-containing protein 4, and bromodomain testis, summarizing their domain architecture and epigenetic regulatory functions. We then synthesize current evidence linking bromodomain and extraterminal protein activity to cardiovascular disease pathogenesis, emphasizing their contributions to major pathological processes, including inflammatory amplification, fibrotic remodeling, dysregulated energy metabolism, aberrant cell proliferation, endothelial-mesenchymal transition, and ferroptotic cell death. Furthermore, we evaluate advances in bromodomain and extraterminal protein inhibitors across preclinical and clinical research, highlighting agents that demonstrate anti-inflammatory, antifibrotic, and cardioprotective efficacy in animal models of cardiovascular disease. By integrating mechanistic and translational evidence, this review provides a framework for understanding bromodomain and extraterminal proteins in cardiovascular diseases and guides the rational design of targeted therapies.

PMID:
42426583
Bibliographic data and abstract were imported from PubMed on 10 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement